Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2-Normal, Node-Positive Breast Cancer: BCIRG-005 Trial
Identifieur interne : 006837 ( Main/Exploration ); précédent : 006836; suivant : 006838Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2-Normal, Node-Positive Breast Cancer: BCIRG-005 Trial
Auteurs : Wolfgang Eiermann [Allemagne, Pologne, Irlande (pays), Espagne, Australie, États-Unis, Canada, Suisse, France, Belgique] ; Tadeusz Pienkowski ; John Crown ; Saeed Sadeghi ; Miguel Martin ; Arlene Chan ; Mansoor Saleh ; Sandeep Sehdev ; Louise Provencher ; Vladimir Semiglazov ; Michael Press ; Guido Sauter ; Mary-Ann Lindsay ; Alessandro Riva ; Marc Buyse ; Philippe Drevot ; Henry Taupin ; John R. MackeySource :
- Journal of clinical oncology [ 0732-183X ] ; 2011.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
Purpose Anthracyclines, taxanes, and alkylating agents are among the most active agents in treatment of adjuvant breast cancer (BC), but the optimal schedule for their administration is unknown. We performed an adjuvant trial to compare the sequential regimen of doxorubicin with cyclophosphamide (AC) followed by docetaxel (ie, AC>T) with the combination regimen of TAC. Patients and Methods Women with node-positive, human epidermal growth factor receptor 2-nonamplified, operable BC were stratified by number of axillary nodes and hormone receptor status and were randomly assigned to adjuvant chemotherapy with six cycles of TAC (75/50/500 mg/m2 every 3 weeks) or four cycles of AC (60/600 mg/m2 every 3 weeks) followed by four doses of docetaxel at 100 mg/m2 every 3 weeks (AC>T). After completion of chemotherapy, radiation therapy was given as indicated, and patients with hormone receptor (HR) -positive disease received adjuvant hormonal therapy with tamoxifen and/or aromatase inhibitors. Results In 30 months, 3,298 patients were enrolled (n = 1,649 in each arm). The major baseline characteristics were well balanced between the groups. At a median follow-up of 65 months, estimated 5-year disease-free survival rates were 79% in both groups (log-rank P = .98; hazard ratio [HR], 1.0; 95%CI, 0.86 to 1.16), and 5-year overall survival rates for both arms were 88% and 89%, respectively (log-rank P = .37; HR, 0.91; 95% CI, 0.75 to 1.11). TAC was associated with more febrile neutropenia and thrombocytopenia, and AC>T was associated with more sensory neuropathy, nail changes, and myalgia. The incidence of neutropenic infection was similar in both groups. Conclusion The sequential and combination regimens incorporating three drugs were equally effective but differed in toxicity profile.
Affiliations:
- Allemagne, Australie, Belgique, Canada, Espagne, France, Irlande (pays), Pologne, Suisse, États-Unis
- Bavière, Californie, Communauté de Madrid, District de Haute-Bavière, Île-de-France
- Los Angeles, Madrid, Munich, Paris
- Université de Californie du Sud
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 001890
- to stream PascalFrancis, to step Curation: 004666
- to stream PascalFrancis, to step Checkpoint: 001799
- to stream Main, to step Merge: 006C50
- to stream Main, to step Curation: 006837
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2-Normal, Node-Positive Breast Cancer: BCIRG-005 Trial</title><author><name sortKey="Eiermann, Wolfgang" sort="Eiermann, Wolfgang" uniqKey="Eiermann W" first="Wolfgang" last="Eiermann">Wolfgang Eiermann</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Women's Hospital</s1><s2>München</s2><s3>DEU</s3></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Breast Cancer Clinic</s1><s2>Warsaw</s2><s3>POL</s3></inist:fA14><country>Pologne</country><wicri:noRegion>Breast Cancer Clinic</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>All-Ireland Co-Operative Oncology Research Group</s1><s2>Dublin</s2><s3>IRL</s3></inist:fA14><country>Irlande (pays)</country><wicri:noRegion>All-Ireland Co-Operative Oncology Research Group</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Hospital Universitario San Carlos</s1><s2>Madrid</s2><s3>ESP</s3></inist:fA14><country>Espagne</country><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Mount Medical Center</s1><s2>Perth</s2><s3>AUS</s3></inist:fA14><country>Australie</country><wicri:noRegion>Mount Medical Center</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>University of Alabama</s1><s2>Birmingham, AL</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><wicri:noRegion>University of Alabama</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>William Osler Health Center, Brampton Civic Hospital</s1><s2>Ontario</s2><s3>CAN</s3></inist:fA14><country>Canada</country><wicri:noRegion>Ontario</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Hôpital Saint Sacrement, Département d'Oncologie, Ville de Quebec</s1><s3>CAN</s3></inist:fA14><country>Canada</country><wicri:noRegion>Hôpital Saint Sacrement, Département d'Oncologie, Ville de Quebec</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Research Institute of Oncology n.a. N.N. Petrov Rosmedtechnologiy, St Petersburg, Russian Federation; University of California Los Angeles</s1><s3>USA</s3></inist:fA14><country>États-Unis</country><wicri:noRegion>Research Institute of Oncology n.a. N.N. Petrov Rosmedtechnologiy, St Petersburg, Russian Federation; University of California Los Angeles</wicri:noRegion></affiliation><affiliation wicri:level="4"><inist:fA14 i1="10"><s1>University of Southern California</s1><s2>Los Angeles, CA</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Los Angeles</settlement><region type="state">Californie</region></placeName><orgName type="university">Université de Californie du Sud</orgName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>University of Basel, Institute of Pathology</s1><s2>Basel</s2><s3>CHE</s3></inist:fA14><country>Suisse</country><wicri:noRegion>Basel</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="12"><s1>Cancer International Research Group</s1><s2>Paris</s2><s3>FRA</s3></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>International Drug Development Institute Statistics</s1><s2>Leuven</s2><s3>BEL</s3></inist:fA14><country>Belgique</country><wicri:noRegion>International Drug Development Institute Statistics</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Cross Cancer Institute, Edmonton</s1><s2>Alberta</s2><s3>CAN</s3></inist:fA14><country>Canada</country><wicri:noRegion>Alberta</wicri:noRegion></affiliation></author><author><name sortKey="Pienkowski, Tadeusz" sort="Pienkowski, Tadeusz" uniqKey="Pienkowski T" first="Tadeusz" last="Pienkowski">Tadeusz Pienkowski</name></author><author><name sortKey="Crown, John" sort="Crown, John" uniqKey="Crown J" first="John" last="Crown">John Crown</name></author><author><name sortKey="Sadeghi, Saeed" sort="Sadeghi, Saeed" uniqKey="Sadeghi S" first="Saeed" last="Sadeghi">Saeed Sadeghi</name></author><author><name sortKey="Martin, Miguel" sort="Martin, Miguel" uniqKey="Martin M" first="Miguel" last="Martin">Miguel Martin</name></author><author><name sortKey="Chan, Arlene" sort="Chan, Arlene" uniqKey="Chan A" first="Arlene" last="Chan">Arlene Chan</name></author><author><name sortKey="Saleh, Mansoor" sort="Saleh, Mansoor" uniqKey="Saleh M" first="Mansoor" last="Saleh">Mansoor Saleh</name></author><author><name sortKey="Sehdev, Sandeep" sort="Sehdev, Sandeep" uniqKey="Sehdev S" first="Sandeep" last="Sehdev">Sandeep Sehdev</name></author><author><name sortKey="Provencher, Louise" sort="Provencher, Louise" uniqKey="Provencher L" first="Louise" last="Provencher">Louise Provencher</name></author><author><name sortKey="Semiglazov, Vladimir" sort="Semiglazov, Vladimir" uniqKey="Semiglazov V" first="Vladimir" last="Semiglazov">Vladimir Semiglazov</name></author><author><name sortKey="Press, Michael" sort="Press, Michael" uniqKey="Press M" first="Michael" last="Press">Michael Press</name></author><author><name sortKey="Sauter, Guido" sort="Sauter, Guido" uniqKey="Sauter G" first="Guido" last="Sauter">Guido Sauter</name></author><author><name sortKey="Lindsay, Mary Ann" sort="Lindsay, Mary Ann" uniqKey="Lindsay M" first="Mary-Ann" last="Lindsay">Mary-Ann Lindsay</name></author><author><name sortKey="Riva, Alessandro" sort="Riva, Alessandro" uniqKey="Riva A" first="Alessandro" last="Riva">Alessandro Riva</name></author><author><name sortKey="Buyse, Marc" sort="Buyse, Marc" uniqKey="Buyse M" first="Marc" last="Buyse">Marc Buyse</name></author><author><name sortKey="Drevot, Philippe" sort="Drevot, Philippe" uniqKey="Drevot P" first="Philippe" last="Drevot">Philippe Drevot</name></author><author><name sortKey="Taupin, Henry" sort="Taupin, Henry" uniqKey="Taupin H" first="Henry" last="Taupin">Henry Taupin</name></author><author><name sortKey="Mackey, John R" sort="Mackey, John R" uniqKey="Mackey J" first="John R." last="Mackey">John R. Mackey</name></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">11-0455906</idno><date when="2011">2011</date><idno type="stanalyst">PASCAL 11-0455906 INIST</idno><idno type="RBID">Pascal:11-0455906</idno><idno type="wicri:Area/PascalFrancis/Corpus">001890</idno><idno type="wicri:Area/PascalFrancis/Curation">004666</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001799</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001799</idno><idno type="wicri:doubleKey">0732-183X:2011:Eiermann W:phase:iii:study</idno><idno type="wicri:Area/Main/Merge">006C50</idno><idno type="wicri:Area/Main/Curation">006837</idno><idno type="wicri:Area/Main/Exploration">006837</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2-Normal, Node-Positive Breast Cancer: BCIRG-005 Trial</title><author><name sortKey="Eiermann, Wolfgang" sort="Eiermann, Wolfgang" uniqKey="Eiermann W" first="Wolfgang" last="Eiermann">Wolfgang Eiermann</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Women's Hospital</s1><s2>München</s2><s3>DEU</s3></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Breast Cancer Clinic</s1><s2>Warsaw</s2><s3>POL</s3></inist:fA14><country>Pologne</country><wicri:noRegion>Breast Cancer Clinic</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>All-Ireland Co-Operative Oncology Research Group</s1><s2>Dublin</s2><s3>IRL</s3></inist:fA14><country>Irlande (pays)</country><wicri:noRegion>All-Ireland Co-Operative Oncology Research Group</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Hospital Universitario San Carlos</s1><s2>Madrid</s2><s3>ESP</s3></inist:fA14><country>Espagne</country><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Mount Medical Center</s1><s2>Perth</s2><s3>AUS</s3></inist:fA14><country>Australie</country><wicri:noRegion>Mount Medical Center</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>University of Alabama</s1><s2>Birmingham, AL</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><wicri:noRegion>University of Alabama</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>William Osler Health Center, Brampton Civic Hospital</s1><s2>Ontario</s2><s3>CAN</s3></inist:fA14><country>Canada</country><wicri:noRegion>Ontario</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Hôpital Saint Sacrement, Département d'Oncologie, Ville de Quebec</s1><s3>CAN</s3></inist:fA14><country>Canada</country><wicri:noRegion>Hôpital Saint Sacrement, Département d'Oncologie, Ville de Quebec</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Research Institute of Oncology n.a. N.N. Petrov Rosmedtechnologiy, St Petersburg, Russian Federation; University of California Los Angeles</s1><s3>USA</s3></inist:fA14><country>États-Unis</country><wicri:noRegion>Research Institute of Oncology n.a. N.N. Petrov Rosmedtechnologiy, St Petersburg, Russian Federation; University of California Los Angeles</wicri:noRegion></affiliation><affiliation wicri:level="4"><inist:fA14 i1="10"><s1>University of Southern California</s1><s2>Los Angeles, CA</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Los Angeles</settlement><region type="state">Californie</region></placeName><orgName type="university">Université de Californie du Sud</orgName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>University of Basel, Institute of Pathology</s1><s2>Basel</s2><s3>CHE</s3></inist:fA14><country>Suisse</country><wicri:noRegion>Basel</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="12"><s1>Cancer International Research Group</s1><s2>Paris</s2><s3>FRA</s3></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>International Drug Development Institute Statistics</s1><s2>Leuven</s2><s3>BEL</s3></inist:fA14><country>Belgique</country><wicri:noRegion>International Drug Development Institute Statistics</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Cross Cancer Institute, Edmonton</s1><s2>Alberta</s2><s3>CAN</s3></inist:fA14><country>Canada</country><wicri:noRegion>Alberta</wicri:noRegion></affiliation></author><author><name sortKey="Pienkowski, Tadeusz" sort="Pienkowski, Tadeusz" uniqKey="Pienkowski T" first="Tadeusz" last="Pienkowski">Tadeusz Pienkowski</name></author><author><name sortKey="Crown, John" sort="Crown, John" uniqKey="Crown J" first="John" last="Crown">John Crown</name></author><author><name sortKey="Sadeghi, Saeed" sort="Sadeghi, Saeed" uniqKey="Sadeghi S" first="Saeed" last="Sadeghi">Saeed Sadeghi</name></author><author><name sortKey="Martin, Miguel" sort="Martin, Miguel" uniqKey="Martin M" first="Miguel" last="Martin">Miguel Martin</name></author><author><name sortKey="Chan, Arlene" sort="Chan, Arlene" uniqKey="Chan A" first="Arlene" last="Chan">Arlene Chan</name></author><author><name sortKey="Saleh, Mansoor" sort="Saleh, Mansoor" uniqKey="Saleh M" first="Mansoor" last="Saleh">Mansoor Saleh</name></author><author><name sortKey="Sehdev, Sandeep" sort="Sehdev, Sandeep" uniqKey="Sehdev S" first="Sandeep" last="Sehdev">Sandeep Sehdev</name></author><author><name sortKey="Provencher, Louise" sort="Provencher, Louise" uniqKey="Provencher L" first="Louise" last="Provencher">Louise Provencher</name></author><author><name sortKey="Semiglazov, Vladimir" sort="Semiglazov, Vladimir" uniqKey="Semiglazov V" first="Vladimir" last="Semiglazov">Vladimir Semiglazov</name></author><author><name sortKey="Press, Michael" sort="Press, Michael" uniqKey="Press M" first="Michael" last="Press">Michael Press</name></author><author><name sortKey="Sauter, Guido" sort="Sauter, Guido" uniqKey="Sauter G" first="Guido" last="Sauter">Guido Sauter</name></author><author><name sortKey="Lindsay, Mary Ann" sort="Lindsay, Mary Ann" uniqKey="Lindsay M" first="Mary-Ann" last="Lindsay">Mary-Ann Lindsay</name></author><author><name sortKey="Riva, Alessandro" sort="Riva, Alessandro" uniqKey="Riva A" first="Alessandro" last="Riva">Alessandro Riva</name></author><author><name sortKey="Buyse, Marc" sort="Buyse, Marc" uniqKey="Buyse M" first="Marc" last="Buyse">Marc Buyse</name></author><author><name sortKey="Drevot, Philippe" sort="Drevot, Philippe" uniqKey="Drevot P" first="Philippe" last="Drevot">Philippe Drevot</name></author><author><name sortKey="Taupin, Henry" sort="Taupin, Henry" uniqKey="Taupin H" first="Henry" last="Taupin">Henry Taupin</name></author><author><name sortKey="Mackey, John R" sort="Mackey, John R" uniqKey="Mackey J" first="John R." last="Mackey">John R. Mackey</name></author></analytic><series><title level="j" type="main">Journal of clinical oncology</title><title level="j" type="abbreviated">J. clin. oncol.</title><idno type="ISSN">0732-183X</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of clinical oncology</title><title level="j" type="abbreviated">J. clin. oncol.</title><idno type="ISSN">0732-183X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvant treatment</term><term>Antineoplastic agent</term><term>Breast cancer</term><term>Cancerology</term><term>Clinical trial</term><term>Comparative study</term><term>Cyclophosphamide</term><term>Docetaxel</term><term>Doxorubicin</term><term>Human</term><term>Human Epidermal growth factor Receptor 2</term><term>Phase III trial</term><term>Sequential</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Essai clinique phase III</term><term>Traitement adjuvant</term><term>Etude comparative</term><term>Doxorubicine</term><term>Séquentiel</term><term>Homme</term><term>Cyclophosphamide</term><term>Essai clinique</term><term>Cancérologie</term><term>Docétaxel</term><term>Cancer du sein</term><term>Anticancéreux</term><term>Récepteur HER2</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Purpose Anthracyclines, taxanes, and alkylating agents are among the most active agents in treatment of adjuvant breast cancer (BC), but the optimal schedule for their administration is unknown. We performed an adjuvant trial to compare the sequential regimen of doxorubicin with cyclophosphamide (AC) followed by docetaxel (ie, AC>T) with the combination regimen of TAC. Patients and Methods Women with node-positive, human epidermal growth factor receptor 2-nonamplified, operable BC were stratified by number of axillary nodes and hormone receptor status and were randomly assigned to adjuvant chemotherapy with six cycles of TAC (75/50/500 mg/m<sup>2</sup> every 3 weeks) or four cycles of AC (60/600 mg/m<sup>2</sup> every 3 weeks) followed by four doses of docetaxel at 100 mg/m<sup>2</sup> every 3 weeks (AC>T). After completion of chemotherapy, radiation therapy was given as indicated, and patients with hormone receptor (HR) -positive disease received adjuvant hormonal therapy with tamoxifen and/or aromatase inhibitors. Results In 30 months, 3,298 patients were enrolled (n = 1,649 in each arm). The major baseline characteristics were well balanced between the groups. At a median follow-up of 65 months, estimated 5-year disease-free survival rates were 79% in both groups (log-rank P = .98; hazard ratio [HR], 1.0; 95%CI, 0.86 to 1.16), and 5-year overall survival rates for both arms were 88% and 89%, respectively (log-rank P = .37; HR, 0.91; 95% CI, 0.75 to 1.11). TAC was associated with more febrile neutropenia and thrombocytopenia, and AC>T was associated with more sensory neuropathy, nail changes, and myalgia. The incidence of neutropenic infection was similar in both groups. Conclusion The sequential and combination regimens incorporating three drugs were equally effective but differed in toxicity profile.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Belgique</li><li>Canada</li><li>Espagne</li><li>France</li><li>Irlande (pays)</li><li>Pologne</li><li>Suisse</li><li>États-Unis</li></country><region><li>Bavière</li><li>Californie</li><li>Communauté de Madrid</li><li>District de Haute-Bavière</li><li>Île-de-France</li></region><settlement><li>Los Angeles</li><li>Madrid</li><li>Munich</li><li>Paris</li></settlement><orgName><li>Université de Californie du Sud</li></orgName></list><tree><noCountry><name sortKey="Buyse, Marc" sort="Buyse, Marc" uniqKey="Buyse M" first="Marc" last="Buyse">Marc Buyse</name><name sortKey="Chan, Arlene" sort="Chan, Arlene" uniqKey="Chan A" first="Arlene" last="Chan">Arlene Chan</name><name sortKey="Crown, John" sort="Crown, John" uniqKey="Crown J" first="John" last="Crown">John Crown</name><name sortKey="Drevot, Philippe" sort="Drevot, Philippe" uniqKey="Drevot P" first="Philippe" last="Drevot">Philippe Drevot</name><name sortKey="Lindsay, Mary Ann" sort="Lindsay, Mary Ann" uniqKey="Lindsay M" first="Mary-Ann" last="Lindsay">Mary-Ann Lindsay</name><name sortKey="Mackey, John R" sort="Mackey, John R" uniqKey="Mackey J" first="John R." last="Mackey">John R. Mackey</name><name sortKey="Martin, Miguel" sort="Martin, Miguel" uniqKey="Martin M" first="Miguel" last="Martin">Miguel Martin</name><name sortKey="Pienkowski, Tadeusz" sort="Pienkowski, Tadeusz" uniqKey="Pienkowski T" first="Tadeusz" last="Pienkowski">Tadeusz Pienkowski</name><name sortKey="Press, Michael" sort="Press, Michael" uniqKey="Press M" first="Michael" last="Press">Michael Press</name><name sortKey="Provencher, Louise" sort="Provencher, Louise" uniqKey="Provencher L" first="Louise" last="Provencher">Louise Provencher</name><name sortKey="Riva, Alessandro" sort="Riva, Alessandro" uniqKey="Riva A" first="Alessandro" last="Riva">Alessandro Riva</name><name sortKey="Sadeghi, Saeed" sort="Sadeghi, Saeed" uniqKey="Sadeghi S" first="Saeed" last="Sadeghi">Saeed Sadeghi</name><name sortKey="Saleh, Mansoor" sort="Saleh, Mansoor" uniqKey="Saleh M" first="Mansoor" last="Saleh">Mansoor Saleh</name><name sortKey="Sauter, Guido" sort="Sauter, Guido" uniqKey="Sauter G" first="Guido" last="Sauter">Guido Sauter</name><name sortKey="Sehdev, Sandeep" sort="Sehdev, Sandeep" uniqKey="Sehdev S" first="Sandeep" last="Sehdev">Sandeep Sehdev</name><name sortKey="Semiglazov, Vladimir" sort="Semiglazov, Vladimir" uniqKey="Semiglazov V" first="Vladimir" last="Semiglazov">Vladimir Semiglazov</name><name sortKey="Taupin, Henry" sort="Taupin, Henry" uniqKey="Taupin H" first="Henry" last="Taupin">Henry Taupin</name></noCountry><country name="Allemagne"><region name="Bavière"><name sortKey="Eiermann, Wolfgang" sort="Eiermann, Wolfgang" uniqKey="Eiermann W" first="Wolfgang" last="Eiermann">Wolfgang Eiermann</name></region></country><country name="Pologne"><noRegion><name sortKey="Eiermann, Wolfgang" sort="Eiermann, Wolfgang" uniqKey="Eiermann W" first="Wolfgang" last="Eiermann">Wolfgang Eiermann</name></noRegion></country><country name="Irlande (pays)"><noRegion><name sortKey="Eiermann, Wolfgang" sort="Eiermann, Wolfgang" uniqKey="Eiermann W" first="Wolfgang" last="Eiermann">Wolfgang Eiermann</name></noRegion></country><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Eiermann, Wolfgang" sort="Eiermann, Wolfgang" uniqKey="Eiermann W" first="Wolfgang" last="Eiermann">Wolfgang Eiermann</name></region></country><country name="Australie"><noRegion><name sortKey="Eiermann, Wolfgang" sort="Eiermann, Wolfgang" uniqKey="Eiermann W" first="Wolfgang" last="Eiermann">Wolfgang Eiermann</name></noRegion></country><country name="États-Unis"><noRegion><name sortKey="Eiermann, Wolfgang" sort="Eiermann, Wolfgang" uniqKey="Eiermann W" first="Wolfgang" last="Eiermann">Wolfgang Eiermann</name></noRegion><name sortKey="Eiermann, Wolfgang" sort="Eiermann, Wolfgang" uniqKey="Eiermann W" first="Wolfgang" last="Eiermann">Wolfgang Eiermann</name><name sortKey="Eiermann, Wolfgang" sort="Eiermann, Wolfgang" uniqKey="Eiermann W" first="Wolfgang" last="Eiermann">Wolfgang Eiermann</name></country><country name="Canada"><noRegion><name sortKey="Eiermann, Wolfgang" sort="Eiermann, Wolfgang" uniqKey="Eiermann W" first="Wolfgang" last="Eiermann">Wolfgang Eiermann</name></noRegion><name sortKey="Eiermann, Wolfgang" sort="Eiermann, Wolfgang" uniqKey="Eiermann W" first="Wolfgang" last="Eiermann">Wolfgang Eiermann</name><name sortKey="Eiermann, Wolfgang" sort="Eiermann, Wolfgang" uniqKey="Eiermann W" first="Wolfgang" last="Eiermann">Wolfgang Eiermann</name></country><country name="Suisse"><noRegion><name sortKey="Eiermann, Wolfgang" sort="Eiermann, Wolfgang" uniqKey="Eiermann W" first="Wolfgang" last="Eiermann">Wolfgang Eiermann</name></noRegion></country><country name="France"><region name="Île-de-France"><name sortKey="Eiermann, Wolfgang" sort="Eiermann, Wolfgang" uniqKey="Eiermann W" first="Wolfgang" last="Eiermann">Wolfgang Eiermann</name></region></country><country name="Belgique"><noRegion><name sortKey="Eiermann, Wolfgang" sort="Eiermann, Wolfgang" uniqKey="Eiermann W" first="Wolfgang" last="Eiermann">Wolfgang Eiermann</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006837 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006837 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:11-0455906
|texte= Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2-Normal, Node-Positive Breast Cancer: BCIRG-005 Trial
}}
| This area was generated with Dilib version V0.6.33. |  |